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Abstract
Approximately half of estrogen receptor (ER) positive breast tumors will fail to respond to endocrine therapy. Here we used
an integrative bioinformatics approach to analyze three gene expression profiling data sets from breast tumors in an
attempt to uncover underlying mechanisms contributing to the development of resistance and potential therapeutic
strategies to counteract these mechanisms. Genes that are differentially expressed in tamoxifen resistant vs. sensitive breast
tumors were identified from three different publically available microarray datasets. These differentially expressed (DE)
genes were analyzed using gene function and gene set enrichment and examined in intrinsic subtypes of breast tumors.
The Connectivity Map analysis was utilized to link gene expression profiles of tamoxifen resistant tumors to small molecules
and validation studies were carried out in a tamoxifen resistant cell line. Despite little overlap in genes that are differentially
expressed in tamoxifen resistant vs. sensitive tumors, a high degree of functional similarity was observed among the three
datasets. Tamoxifen resistant tumors displayed enriched expression of genes related to cell cycle and proliferation, as well as
elevated activity of E2F transcription factors, and were highly correlated with a Luminal intrinsic subtype. A number of small
molecules, including phenothiazines, were found that induced a gene signature in breast cancer cell lines opposite to that
found in tamoxifen resistant vs. sensitive tumors and the ability of phenothiazines to down-regulate cyclin E2 and inhibit
proliferation of tamoxifen resistant breast cancer cells was validated. Our findings demonstrate that an integrated
bioinformatics approach to analyze gene expression profiles from multiple breast tumor datasets can identify important
biological pathways and potentially novel therapeutic options for tamoxifen-resistant breast cancers.
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Introduction
Estrogen action through estrogen receptor alpha (ER) is a
critical regulator of breast cancer cell proliferation and survival.
Tamoxifen is an ER antagonist that competitively inhibits the
interaction of estrogen with ER and represses ER activity [1,2,3].
Tamoxifen has been the primary therapeutic choice in both early
and advanced ER positive breast cancer patients since the 1970s.
Unfortunately, up to 50% of patients with metastatic disease do
not respond to first-line treatment with tamoxifen, and many who
receive it as adjuvant therapy experience relapse despite an initial
response. Understanding mechanisms by which resistance devel-
ops is an important task, which could lead to new therapeutic
strategies to combat tumors resistant to endocrine therapy.
Recently, microarray gene expression profiling of ER+ breast
tumors has been used to identify gene signatures for prediction of
clinical outcome of patients treated with tamoxifen [4,5,6,7,8]. For
example, a 36-gene signature has been derived that can correctly
classify up to 80% of patients into relapse or relapse-free groups
[7]. Similarly, a 44-gene signature and a 181-gene signature of
tamoxifen responsiveness have also been developed from profiling
different tumor sets [5,8]. These gene expression studies were
primarily focused on the identification of gene signatures
associated with disease progression and clinical outcomes.
Therefore, genes in the signatures are not necessarily directly
involved in mediating sensitivity to tamoxifen or regulating tumor
growth. Furthermore, the analyses of molecular functions of these
signature genes have provided only limited insight into underlying
mechanisms related to the treatment failure. For example, a
preliminary functional analysis of the 36-gene signature in
Chanrion et al. [7] indicates that there were 23 under-expressed
and 13 were over-expressed genes in tumors from patients with
relapse compared to tumors that were relapse free. The under-
expressed genes were involved in cellular adhesion or invasion,
immune responses, and ER negative regulation, whereas the over-
expressed genes were involved in control of mitosis and cell cycle,
DNA replication, DNA repair. The 44-gene signature was derived
from a set of 81 DE genes that are involved in estrogen action,
apoptosis, and extracellular matrix based on functional annotation
[8]. On the other hand, the 181-genes in the signature developed
by Loi et al. [5] was created from 13 biological clusters determined
in the context of a curated list of published molecular interactions
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biological functions such as cell cycle, cell death, DNA repair and
cancer inflammation among others. However, whether these
functions were represented by the over- or under-expressed genes
in the tamoxifen resistant tumors was not clear. Also of note, the
three published gene signatures are comprised of distinctly
different sets of genes with a small overlap, which presents
challenges in deriving any potential mechanisms that may underlie
the development of tamoxifen resistance.
We therefore undertook a systematic analysis of three publically
available microarray data sets to better understand the biological
mechanisms that may contribute to a tamoxifen resistant phenotype
[5,6,7]. Interestingly, there was little overlap between the three
datasets in terms of individual genes that are differentially expressed
in tamoxifen resistant vs. sensitive tumors. However, a variety of
bioinformatics analyses revealed several functional commonalities in
these gene sets, including enhanced cell cycle potential, elevated
activity of the target genes of the E2F family of transcription factors,
and a number of small molecules that can reverse expression of genes
associated with tamoxifen resistance. Finally, we validated the
functionality of three small molecules from the phenothiazine family
of anti-psychotic drugs to down-regulate cyclin E2 expression and
inhibit proliferation of tamoxifen resistant breast cancer cells. Taken
together, our findings demonstrate that an integrated approach to
analyzing disparate datasets can produce valuable biological
information and lead to potential novel therapeutic strategies for
drug resistant breast cancers.
Materials and Methods
Breast tumor microarray data sets
Datasets used in this work were selected from three breast
cancer microarray studies published previously [5,6,7] and the raw
data were downloaded from Gene Expression Omnibus [9]
(accession numbers GSE6532, GSE9195 and GSE9893). Briefly,
datasets GSE6532 and GSE9195 consist of gene expression
profiles of early stage breast cancer tumors diagnosed between
1980 and 1995 in the John Radcliffe Hospital, Oxford, United
Kingdom and Guys Hospital, London, United Kingdom and
Uppsala University Hospital, Uppsala, Sweden, respectively. All
tumors were required to be ER positive and had received
tamoxifen only as adjuvant treatment. Dataset GSE9893 contains
gene expression profiles on breast tumors obtained from patients
between 1989 and 2001 at the Cancer Research Center of Val
d’Aurelle in Montpellier, the Bergonie ´ Institute of Bordeaux, or
the Department of Obstetrics and Gynecology of Turin. The
patients received tamoxifen treatment for 5 years after surgery.
Some of them also received adjuvant radiotherapy. Tumors from
each study were classified as tamoxifen sensitive if patients were
relapse-free for 5 years or greater or tamoxifen resistant if relapse
occurred within 5 years [10]. The 5-year cut-off is based on the
criterion published in [10,11].
Gene expression analysis
Gene expression analysis was performed using packages in
Bioconductor [12]. For each microarray dataset, the probe set
intensities were normalized and summarized using the Robust
Multichip Averaging algorithm [13] with quantile normalization
in rma package. Affymetrix detection calls were obtained to
remove low quality probe sets. A second procedure was applied to
filter out the least variable probe sets using the percentile of the
distribution of coefficient of variability values. The threshold for
this filtering was set based on the platform using 0.5 for GSE6532
and GSE9195, and 0.8 for GSE9893. The custom CDF file [14]
was used for probe set definition for datasets based on Affymetrix
platforms. For the dataset based on 70-mer oligonucleotide
microarray, the 22,680 oligonucleotide probes (Oligo Set
TM for
the Human Genome Version 2.1.3, Qiagen-Operon) representing
21,329 human specific genes were used. The DE genes between
the tamoxifen resistant and sensitive tumors were identified using
limma package with the Benjamini–Hochberg procedure for
multiple test adjustment [15]. The adjusted P-value threshold was
set at 0.05.
Gene function enrichment analysis
For each microarray dataset, over-expressed and under-expressed
genes in tamoxifen resistant compared to sensitive tumors were tested
for enrichment of functional annotation categories using tools in the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (v6.7) [16]. The P-values for the functional annotation
enrichment were corrected by the Benjamini–Hochberg method for
multiple testing and the significance threshold for the adjusted P-
values was set at 0.1.
Gene set enrichment analysis (GSEA)
GSEAcan detectpathways or gene sets whose expression levels are
different between two phenotypes based on entire microarray profiles
(not just DEgenes)using pre-defined gene sets [17]. Two categories of
pre-defined gene sets were selected for analysis. One was the
canonical pathway gene sets collected from online pathway
databases, biomedical literature, and published mammalian micro-
array studies. The other was a collection of transcription factor target
gene sets, which contain genes that share a transcription factor
binding site defined inthe TRANSFAC (ver7.4) database[18]. These
gene sets are available from the Molecular Signature Database
(MSigDB) [19]. The gene sets included in our analysis were limited to
those with size between 10 and 500 genes. Permutation was carried
out 10,000 times using default weighted enrichment statistic and a
signal-to-noise metric to rank genes according to their differential
expression level across tamoxifen resistant and sensitive tumors. Gene
sets with nominal P-value,0.05 were selected.
Enrichment analysis of differentially expressed genes in
breast cancer subtypes
A compendium of 1211 breast cancer microarray expression
profiles was used for the enrichment analysis of the DE genes
identified by our study in the breast cancer subtypes [20]. These
tumors were classified into distinct subtypes based on available
tumor annotations. There are 441 tumors in Luminal A, 121
tumors in Luminal B, 136 tumors in normal-like, 152 in Her2, and
279 in basal-like subtypes. The expression data, which were
downloaded from the author’s website, have been log2-trans-
formed [20]. Gene expression levels are represented relative to the
mean of each gene, which was calculated from all samples in the
compendium. The enrichment analysis of DE gene sets between
tamoxifen resistant and sensitive tumors in the breast cancer
subtypes was conducted in two steps. First, for each tumor in the
compendium, the up-regulated genes with an expression level
greater than 2 and the down-regulated genes with an expression
level less than 22, relative to the mean expression of each gene
across the compendium, were identified. The enrichment of over-
expressed genes from the tamoxifen resistant tumors in the up-
regulated gene set from the compendium was analyzed using the
hypergeometric test. Similarly, the enrichment of under-expressed
genes from the tamoxifen resistant tumors in the down-regulated
gene set from the compendium was also analyzed. The
significantly enriched tumors were identified using a threshold of
Bioinformatics Approach to Resistant Breast Tumors
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cancer subtype was assigned a P-value according to the
hypergeometric test with a threshold of P,0.01 for significance.
Survival analysis
The principal component analysis (PCA) has been performed for
the untreated Luminal A and Luminal B tumors in the compendium
set using each of the three DE gene sets (genes not presented in the
compendium were excluded). The hierarchical clustering was based
on the weights of expression on the top principal components which
account for more than 48% of the variance. The Kaplan-Meier
e s t i m a t e sw e r eu s e dt oc o m p u t et h es u r v i v a lc u r v e s .T h ep a c k a g e si n
R were used for the above analyses.
Connectivity Map analysis
Entrez gene identifiers of the DE genes in the three microarray
datasets were first mapped to Affymetrix HG-U133A probe sets
using Affymetrix Human Genome U133A set annotation data
implemented in package hgu133a.db in Bioconductor. All mapped
probe sets in each individual microarray dataset were then
submitted to the Connectivity Map website [21]. A connectivity
score based on the Kolmogorov-Smirnov statistic was calculated to
estimate the enrichment of both over- and under-expressed query
genes in a Connectivity Map instance as described [22]. As the
basic unit of data in Connectivity Map, an instance consists of the
expression profile of a cell line treated with a compound at a
certain concentration and its control pair, as well as a rank-
ordered list of all probe sets on the HG-U133A array based on the
differential expression level between the pair. The current version
of the Connectivity Map (build 02) contains 6,100 such instances
representing 5 cultured human cell lines treated with 1,309
compounds. Instances were ranked in descending order of
connectivity scores. Multiple independent instances of the same
compound with high (or low) rankings indicate positive (or
negative) connectivity between the compound and the phenotype
represented by the query gene lists. Permutation tests were
performed to estimate the significance of the instance sets ranked
by the connectivity scores. Compounds were selected from top
ranked instance sets with negative connectivity scores at
permutation P-value,0.05 for each individual inquiry gene list.
Cell culture and reagents
MCF-7 breast cancer cell lines that were sensitive to tamoxifen
or had developed spontaneous resistance to tamoxifen but
remained highly responsive to estradiol (Figure S1) were cultured
as previously described [23]. BT474 cells were cultured as
previously described [24]. 4-hydroxytamoxifen, trifluoperazine,
thioridazine, and prochlorperazine were all obtained from Sigma
and used to treat cells, as described in the figure legend, following
3-day incubation in phenol-red free medium supplemented with
charcoal-dextran stripped serum.
Cell viability and proliferation
Cell viability was determined by methylene blue staining [25].
Briefly, each well was rinsed once with PBS and methylene blue
staining solution (Hanks’ Balanced Salt Solution+1.25% glutaral-
dehyde+0.6% methylene blue) was added to each well. Following
1 h incubation at 37uC, methylene blue staining solution was
removed, and the plates were gently rinsed 3 times in ddH2O.
Elution solution (50% ethanol+49% PBS+1% acetic acid) was
added to each well and subsequently incubated for 20 min at room
temperature with gentle agitation. Absorbance was read on a
microplate reader at a wavelength of 562 nm and viability was
calculated as a percentage of control cells. To study the specific
effects of phenothiazines on proliferation, a BrdU assay was
carried according to the manufacturer’s instructions (Millipore,
Billerica, MA). For this assay, MCF 7 cells were treated with
phenothiazines for 48 hr with BrdU applied to the cells for the
final 24 hours of treatment. Cells were fixed for 30 min and then
incubated with anti-BrdU antibody for 1 hour. The goat anti-
mouse antibody conjugated to peroxidase was added for 30 min.
After washing, cells were incubated with peroxidase substrate for
30 min. Absorbance, correlating to BrdU uptake by the cells, was
read at 450 nm wavelength on an automated plate-reader.
Cyclin E2 mRNA expression
Following treatment of tamoxifen-resistant MCF-7 cells with
phenothiazines for 24 hr, total RNA was isolated and Cyclin E2
mRNA was examined by QPCR as previously described [23] using
primers specific for Cyclin E2: forward: 59-GACGGAATCCCCC-
CAAGA-39, reverse: 59-TTTTTTGACATCCTGGGTAGTTT-
TC-39. The expression of cyclin E2 following treatment relative to
vehicle treated control cells was determined by the DDCT method
from three independent experiments.
Results
Differentially expressed genes in tamoxifen resistant vs.
sensitive breast tumors from three microarray datasets
Three sets of microarray gene expression profiles from ER
positive breast tumors were obtained from Gene Expression
Omnibus as described in Materials and Methods. The numbers of
tumors included from each dataset along with the information on
the microarray platforms are shown in Table 1 based on the 5-
year cut-off for tamoxifen resistance. After filtering out non-
variable genes from each dataset, the total numbers of genes
analyzed were 3,064, 4,870 and 2,366 for GSE6532, GSE9195
and GSE9893, respectively. The numbers of DE genes, which
were either over-expressed or under-expressed in tamoxifen
resistant compared to sensitive tumors, are 275 for GSE6532,
130 for GSE9195, and 252 for GSE9893. (A 10-year cut-off was
also considered, but the dataset GSE6532 did not provide any
differentially expressed genes at FDR=0.05 following the same
analysis protocol). The full list of the DE genes can be found in
Table S1. The Venn diagram of overlap of the DE genes among
these three datasets is shown in Figure 1. Surprisingly, there are
only four genes common in all three sets of DE genes. These are
chemokine C-X3-C motif receptor 1 (CX3CR1), which is under-
expressed in tamoxifen resistant tumors; cyclin E2 (CCNE2),
kinesin family member 4A (KIF4A) and non-SMC condensin I
complex, and subunit G (NCAPG), which are over-expressed in
tamoxifen resistant tumors. Furthermore, there was very little
overlap between any two data sets with just 16 common between
GSE6532 and GSE9195, 14 common between GSE9195 and
GSE9893, and 14 common between GSE6532 and GSE9893.
These findings suggest that either the underlying biology is very
different among these three sets of tumors or that some technical
aspect of performing the microarrays captured unique sets of DE
genes.
Common biological pathways identified in tamoxifen
resistant tumors
To examine whether the datasets in fact represent biologically
different phenotypes, a number of approaches were utilized to
compare the three sets of DE genes. First, a functional analysis was
performed for each individual dataset using the tools in DAVID.
This analysis allows for the identification of particular biological
Bioinformatics Approach to Resistant Breast Tumors
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22274processes or pathways based on functional annotation categories
that are over-represented in a set of genes. The three sets of genes
that are over-expressed in tamoxifen resistant tumors share a large
number of enriched Gene Ontology (GO) terms (Table 2).
Specifically, the GO terms in common are mainly associated with
cell cycle and DNA replication, suggesting elevated cell prolifer-
ative capacity in tamoxifen resistant compared to sensitive tumors.
On the other hand, there are no common GO terms shared in the
three sets of under-expressed genes in tamoxifen resistant tumors.
The entire list of enriched GO terms for each dataset is provided
in Table S2. These findings suggest that although there is little
overlap of individual genes among the tamoxifen resistant and
sensitive tumors, there may be similar underlying biological
mechanisms represented in these data sets.
To infer the possible mechanisms underlying the altered gene
expression profiles in tamoxifen resistant tumors, we performed GSEA
[17] to determine if specific pre-defined gene sets were significantly
enriched in tamoxifen resistant tumors. Four canonical pathways,
DNA replication reactome, G1_to_S cell cycle reactome, HSA04110
cell cycle, and purine metabolism, were found to be commonly
enriched pathways among all three datasets. Over-expressed genes,
POLE3,PRIM1,RFC3,RFC4,RFC5 (in GSE6532),DBF4,GMNN,
FEN1, MCM10, PSMD12 (in GSE9195) and CCNA2, CDC6,
CDT1, MCM2, MCM4 (in GSE9893), are involved in DNA
replication. Other over-expres s e dg e n e ss u c ha sC C N A 2( i n
GSE9893), CCNE2 (in GSE6532, GSE9195 and GSE9893), and
CCNB2, CDC2, KIF2C, RRM2 (in GSE9195 and GSE9893) are
associated with the cell cycle pathways. This finding suggests that
tamoxifen resistant tumors likely have an intrinsically elevated level of
cell proliferation. This concept was further supported by GSEA with
transcription factor (TF) target gene sets. The analysis is designed to
examine whether activity of a specific TF is significantly associated with
given gene expression data. In the case of tamoxifen resistant tumors,
target genes for the TFs TFDP1, TFDP2, E2F1, and E2F4 were found
to be significantly enriched in all three microarray datasets (Table 3).
TFDP1 and TFDP2 are transcriptional coactivators that can stimulate
E2F-dependent transcription of a number of genes whose products are
involved in control of cell-cycle progression from G1 to S phase, DNA
replication, and p53-dependent/independent apoptosis [26]. In our
analysis the expression levels of all four TFs are not significantly altered
between tamoxifen resistant and sensitive tumors. However, genes
known to be regulated by these TFs were over-expressed in tamoxifen
resistant tumors; for example, FBXO5 (in GSE6532), TOPBP1 (in
GSE9195), MCM2, MCM4, CDC6 (in GSE9893), and CDC2 (in
GSE9195 and GSE9893). All enriched pathways and TF target gene
sets are given in Table S3. Thus, our findings from the enrichment
analyses of functional annotation, canonical pathway, and TF target
gene sets are all consistent with the concept that elevated cell
proliferation pathways are a hallmark of tamoxifen resistant breast
tumors.
Enrichment of the differentially expressed genes in
breast cancer subtypes
To explore whether the DE genes in tamoxifen resistant vs.
sensitive tumors were enriched in specific intrinsic subtypes of
breast cancer, a breast cancer compendium was utilized as
described in Materials and Methods. Table 4 shows that genes
over-expressed in tamoxifen resistant tumors are enriched in the
Luminal B tumor subtype for two of three datasets, in the Basal-
like tumor subtypes for all three datasets, and the Her2 subtype for
only 1 dataset. In contrast, genes under-expressed in tamoxifen
resistant tumors are enriched in Luminal A subtype tumors for all
three datasets. In addition, the average expression level of CCNE2
is consistently higher in Luminal B, Basal-like, and Her2 tumor
subtypes than average, and lower than average in Luminal A and
Normal-like tumor subtypes (Figure 2). In addition, the transcrip-
tion factor target gene sets of E2F1 and TFDP1 used in GSEA
were also enriched in Luminal B tumor subtype (P=0.014 and
P=0.006, respectively) while TFDP2 and E2F4 target gene sets
showed no enrichment in Luminal B subtype (P=0.302 and
Figure 1. Venn diagram showing overlap between three sets of
differentially expressed genes. The numbers of differentially
expressed genes, which were either over-expressed or under-expressed in
tamoxifen-resistant compared to sensitive tumors, are 275 for GSE6532, 130
for GSE9195, and 252 for GSE9893.
doi:10.1371/journal.pone.0022274.g001
Table 1. Characterization of the data sets from tamoxifen resistant and sensitive breast tumors used in this study.
Number of tumors Number of differentially expressed genes
Data source Platform
Tamoxifen
resistant
Tamoxifen
sensitive
Over-expressed
in tamoxifen
resistant
Under-expressed in
tamoxifen resistant
Total number
of genes
GSE6532 Affymetrix HG-U133A 85 91 173 102 275
GSE9195 Affymetrix HG-U133 Plus 2.0 26 138 86 44 130
GSE9893 Qiagen-Operon Oligo Set 2.1.3 49 98 118 134 252
doi:10.1371/journal.pone.0022274.t001
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Ontology Accession number Synonyms
Biological process GO:0000087 M phase of mitotic cell cycle
GO:0000278 mitotic cell cycle
GO:0000279 M phase
GO:0000280 nuclear division
GO:0006259 DNA metabolic process
GO:0006260 DNA replication
GO:0007049 cell cycle
GO:0007067 mitosis
GO:0007346 regulation of mitotic cell cycle
GO:0010564 regulation of cell cycle process
GO:0022402 cell cycle process
GO:0022403 cell cycle phase
GO:0048285 organelle fission
GO:0051301 cell division
GO:0051726 regulation of cell cycle
Cellular component GO:0000777 condensed chromosome kinetochore
GO:0000779 condensed chromosome, centromeric region
GO:0000793 condensed chromosome
GO:0005694 chromosome
GO:0005819 spindle
GO:0015630 microtubule cytoskeleton
GO:0043228 non-membrane-bounded organelle
GO:0043232 intracellular non-membrane-bounded organelle
GO:0044427 chromosomal part
GO:0044430 cytoskeletal part
Molecular function GO:0001882 nucleoside binding
GO:0001883 purine nucleoside binding
GO:0005524 ATP binding
GO:0030554 adenyl nucleotide binding
GO:0032559 adenyl ribonucleotide binding
doi:10.1371/journal.pone.0022274.t002
Table 3. Transcription factor (TF) binding sites and the putative TFs that are common among all three microarray datasets of
tamoxifen resistant tumors.
Name of response element Putative TF associated with enriched target genes
V$E2F_Q3_01 TFDP1: transcription factor Dp-1
V$E2F_Q4_01 TFDP1: transcription factor Dp-1
V$E2F_Q6 E2F1: E2F transcription factor 1
V$E2F_Q6_01 TFDP1: transcription factor Dp-1
V$E2F1_Q3 E2F1: E2F transcription factor 1
V$E2F1_Q6 E2F1: E2F transcription factor 1
V$E2F1_Q6_01 E2F1: E2F transcription factor 1
V$E2F1DP1_01 E2F1: E2F transcription factor 1; TFDP1: transcription factor Dp-1
V$E2F1DP2_01 E2F1: E2F transcription factor 1; TFDP2: transcription factor Dp-2 (E2F dimerization partner 2)
V$E2F4DP1_01 E2F4: E2F transcription factor 4, p107/p130-binding; TFDP1: transcription factor Dp-1
V$E2F4DP2_01 E2F4: E2F transcription factor 4, p107/p130-binding; TFDP2: transcription factor Dp-2 (E2F dimerization partner 2)
doi:10.1371/journal.pone.0022274.t003
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tumors from the Luminal B intrinsic subtype share a similar highly
proliferative phenotype with tamoxifen resistant tumors.
We further investigated whether using the DE genes between
tamoxifen resistant and sensitive tumors can stratify ER+ tumors
with distinct outcome. For this purpose, we selected a subset of
untreated ER+ tumors (110 Luminal A and 52 Luminal B) with
survival data from the compendium. We retrieved the expression
values of the DE genes for these tumors. A PCA analysis was
performed on their gene expression values corresponding to each
DE set as described in Materials and Methods. Hierarchical
clustering was performed using each of the three DE gene set
(Figure 3A). We stratified the tumors into two clusters. Most of the
Luminal B tumors appeared in cluster 1, but mixed with some
Luminal A tumors, largely seen in the clustering corresponding to
the third gene set. The Kaplan-Meier analysis shows that the two
clusters are significantly different in outcomes, with P=0.001,
P=2e-06 and P=2e-05, respectively for the three DE gene sets
(Figure 3B). This indicates the Luminal B subtypes has a similarly
intrinsic molecular profile to that of the tamoxifen resistant
tumors. Although some Luminal B tumors were present in cluster1
for all three datasets, the two Luminal B subgroups did not show
significantly different outcome (data not shown). However, it was
surprising to observe that in two cases the luminal A tumors
stratified into the two clusters demonstrated a significant difference
in outcome (P=0.47, P=0.029 and P=0.017, respectively)
(Figure 3C). It appears that within the Luminal A tumors, there
is a subgroup of tumors possessing a molecular profile similar to
that of the tamoxifen resistant tumors. These results may appear to
be contradictory to the enrichment findings in Table 4, as the
Luminal A subtype was not significantly enriched in the over-
expressed genes in the tamoxifen resistant tumors. However, this
does not exclude the existence of some Luminal A tumors being
actually enriched by the over-expressed genes.
Small molecules that reverse proliferation of tamoxifen
resistant cell lines
In an attempt to link the gene expression profiles derived from
the tamoxifen resistant and sensitive tumors to small molecules
that may alter the profiles, and potentially tamoxifen resistance, an
analysis was performed using the Connectivity Map [22,27] as
described in Materials and Methods. The Connectivity Map
allows researchers to screen compounds by comparing a ranked
list of genes based on the association to a disease phenotype with
the expression profiles derived from the several types of cell lines
treated with compounds. If a small molecule produces the gene
expression pattern opposite to those observed between tamoxifen
resistant and sensitive breast cancers, then a negative score will be
assigned based on the Connectivity Map analysis. The molecules
with negative scores will be considered to have potential to reverse
the tumor expression pattern if the tumors were treated with the
molecules. The top-ranked compound/cell combinations with
negative connectivity scores that are common among the three
tamoxifen resistant gene sets are listed in Table 5. The entire list of
enriched compounds for each individual microarray dataset can
be found in Table S5.
Among the top-ranked compounds listed in Table 5, three drugs
(trifluoperazine, thioridazine, and prochlorperazine) belong to the
same structural family of phenothiazine compounds. From the
Connectivity Map database, expression of cyclin E2 was found to be
lower in MCF-7 and PC3 cells treated with these three compounds
than in controls (data not shown). To validate whether these drugs
may have any effect on proliferation or gene expression in tamoxifen
resistant breast cancer cells, MCF-7 cells that developed spontaneous
resistance to tamoxifen were utilized (Figure S1). Cells were treated
with increasing concentrations of the three phenothiazines, trifluo-
perazine, thioridazine, and prochlorperazine in the presence of 4-
Table 4. P-values of gene set enrichment analysis on the breast cancer compendium.
Subtypes and numbers in BC
compendium Over-expressed genes in tamoxifen resistant tumors Under-expressed genes in tamoxifen resistant tumors
GSE6532 GSE9195 GSE9893 GSE6532 GSE9195 GSE9893
Luminal A (411) 1.000 1.000 1.000 ,0.001 0* 0*
Luminal B (212) ,0.001 0.217 ,0.001 1.000 0.770 0.523
Normal-like (136) 1.000 1.000 1.000 ,0.001 0.913 0.414
Her2 (152) 0.292 0.276 0* 1.000 1.000 1.000
Basal (270) 0.002 0* ,0.001 1.000 1.000 1.000
*P-values are smaller than 1.00E-15.
doi:10.1371/journal.pone.0022274.t004
Figure 2. Expression level of Cyclin E2 mRNA in breast tumors
from different intrinsic subtypes. The mean expression level of
Cyclin E2 was determined in breast tumors of different intrinsic
subtypes as described in Materials and Methods. The Log2 transformed
mean expression level is relative to the mean expression level in all
tumors in the breast tumor compendium.
doi:10.1371/journal.pone.0022274.g002
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dependent decrease in the number of viable cells was observed for
each of the phenothiazine compounds independent of the presence of
4OHT(Figure4A).Asimilargrowthinhibitoryeffectwasobservedin
MCF-7 cells sensitive to tamoxifen (data not shown). A BrdU assay
was carried out in the resistant cells after 48 hr of treatment and
demonstrates that the growth inhibitory effects of phenothiazines are
associated with a reduction in cell proliferation (Figure 4B). To
examine the effect of these compounds on cyclin E2 expression,
QPCR was carried out. All three phenothiazines down-regulated
expression of cyclin E2 mRNA levels within 24 hr of treatment
(Figure 4C). To confirm our findings in another cell line, we utilized
BT474 cells that over-express HER2 and have previously been
shown to be tamoxifen resistant [28,29]. Treatment with 5 mMo f
prochlorperazine in the presence or absence of 4OHT significantly
inhibited cell proliferation and reduced cyclin E2 mRNA levels
(Figure 5). These findings validate the bioinformatics analyses
described above and identify a novel class of therapeutic drugs that
have the potential to inhibit proliferation of both tamoxifen-sensitive
and tamoxifen-resistant breast tumors.
Discussion
In an attempt to understand more clearly the molecular
mechanisms involved in tamoxifen resistant breast tumors, we
Figure 3. Results of clustering and survival analysis. (A) Clustering results of untreated Luminal A and Luminal B breast tumors from the
compendium gene expression profile using principle components of the DE genes identified in GSE6532 (left), GSE9195 (middle) and GSE9893 (right).
Green: luminal A tumors; Pink: luminal B tumors; (B) Kaplan-Meier estimation of survival for stratified ER+ tumors using the DE genes identified in
GSE6532 (left), GSE9195 (middle) and GSE9893 (right); the number in the parentheses is the number of ER+ tumors in each cluster. (C) Kaplan-Meier
estimation of survival for stratified Luminal A tumors using the DE genes identified in GSE6532 (left), GSE9195 (middle) and GSE9893 (right); the
number in the parentheses is the number of Luminal A tumors in each cluster.
doi:10.1371/journal.pone.0022274.g003
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22274Table 5. Common top ranked compounds with expression profiles opposite to those of the tamoxifen resistance tumors.
GSE6532 GSE9195 GSE9893
Compound Cell Line Enrich Score Rank P * Enrich Score Rank P * Enrich Score Rank P *
trichostatin A PC3 20.372 1 0 20.844 1 0 20.627 2 0
trichostatin A MCF7 20.281 12 0 20.59 3 0 20.58 3 0
LY-294002 MCF7 20.374 3 ,0.001 20.412 4 0 20.441 5 0
resveratrol MCF7 20.696 9 0.002 20.767 13 ,0.001 20.551 143 0.031
trifluoperazine MCF7 20.53 24 0.007 20.641 14 0 20.642 11 0
thioridazine PC3 20.671 29 0.009 20.896 6 ,0.001 20.872 6 ,0.001
DL-thiorphan MCF7 20.933 32 0.009 20.886 73 0.026 20.905 92 0.018
harmine MCF7 20.929 26 0.011 20.948 31 0.006 20.927 67 0.011
0297417-0002B MCF7 20.928 38 0.011 20.977 20 0.001 20.973 21 0.001
chrysin MCF7 20.907 51 0.017 20.943 35 0.007 20.887 116 0.025
trimethylcolchicinic acid MCF7 20.896 62 0.021 20.894 68 0.022 20.911 89 0.016
galantamine MCF7 20.868 92 0.035 20.92 46 0.013 20.916 77 0.014
*P-values of 0 are smaller than 1.00E-15.
doi:10.1371/journal.pone.0022274.t005
Figure 4. Phenothiazines inhibit proliferation and down-regulate Cyclin E2 expression in tamoxifen-resistant MCF-7 breast cancer
cells. (A) Cells were treated for five days with increasing doses of the three phenothiazine compounds in the absence or presence of 1 mM
4-hydroxytamoxifen (4OHT) as indicated. Cell viability was determined by methylene blue staining and expressed as % of vehicle treated control cells.
(B) A BrdU assay was carried out after 48 hr of treatment with 5 mM of each phenothiazine drug. (C) Cyclin E2 mRNA levels were determined by QPCR
following 24 hr treatment with 5 mM of each phenothiazine as indicated. All data represent the mean +/2 SEM from three independent
determinations. *, P,0.05, **, P,0.01.
doi:10.1371/journal.pone.0022274.g004
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three published gene expression datasets from ER positive breast
tumors. It should be noted that these datasets have been previously
analyzed individually to derive gene signatures for the prediction
of tamoxifen responsiveness and clinical outcomes; limited
information on functionality of these genes have been provided
through gene function annotation or pathway analysis [5,6,7].
However, these datasets have not been compared or analyzed
together in any comprehensive manner. Our initial analysis
revealed only four genes that were differentially expressed between
tamoxifen resistant and sensitive tumors and common among all
three datasets. Despite this apparent difference in gene expression
profiles, a variety of functional analyses revealed a high degree of
biological commonality between these tumor sets. This success of
our approach may be attributed to the power of GSEA [17],
which does not rely on a set of DE genes but rather uses a
knowledge-based approach to identify pathways enriched by genes
with a moderate but not significant level of differential expression.
In addition, gene set enrichment analysis using the pre-defined
transcription factor target gene sets enabled the detection of
transcription factors whose activity but not expression levels are
different in resistant and sensitive tumors. Furthermore, the
Connectivity Map analysis allows for the detection of small
molecules that are linked to tamoxifen resistance through analysis
of similarity or dissimilarity between entire gene expression
profiles. Using existing knowledge of pathways and regulation of
gene expression, these approaches appear to be more effective
compared with any single-gene analysis, which may miss
important biologically active pathways.
It should be noted that a different approach can be taken by
pooling tumors profiled with the similar platforms, such as the
U133A, U133B and U133 Plus 2.0 Affymetrix GeneChips. In fact,
we also performed the analysis by pooling tumors in GSE6532 and
GSE9195 sets using common probesets between U133A and
U133 Plus 2.0 chips. Although a larger common DE gene set was
identified, we did not find significant difference in the sets of
enriched GO terms and pathways. However, the effectiveness of
the pooled analysis has to rely on a proper procedure of batch-
effect removal.
A wide variety of proposed mechanisms for tamoxifen
resistance have been described [30] but the majority of these
have been identified using cell lines that have acquired resistance
to tamoxifen over long-term exposure. The gene expression
profiles utilized for our study, on the other hand, are taken from
primary breast tumors prior to exposure to tamoxifen. Thus, our
findings potentially represent de novo or intrinsic molecular
mechanisms of resistance. One gene over-expressed in all three
datasets, cyclin E2, which is an essential regulator of G1 to S
phase transition during the cell cycle, is of particular interest.
Previous studies have shown that over-expression of cyclin E2 in
cell lines is associated with the development of tamoxifen
resistance [31]. In human breast tissue it was found that cyclin
E2 levels are elevated in tumors vs. normal tissue [32] and that
both cyclin E1 and E2 protein levels are associated with a poor
response to tamoxifen [33].
In addition to cyclin E2, the integrated analyses that we
performed also identified several pathways and GO terms, in
particular related to cell proliferation, that are enriched in all three
tamoxifen resistant tumor sets. Furthermore, we find activity of the
E2F family of transcription factors is strongly associated with the
tamoxifen resistant phenotype in all three datasets. Interestingly,
one of the gene expression profiling datasets used in our analysis
was previously used to identify elevated c-Myc activity as
associated with enhanced proliferation signature and reduced
responsiveness to tamoxifen [34]. We have confirmed their
findings (Table S3) but were unable to detect an elevated c-Myc
signature in the other two datasets examined, which indicates the
importance of an integrated analysis for the identification of
common mechanisms implied in different microarray datasets. We
have detected a strong association between tamoxifen resistance
and cell proliferation/cell cycle gene expression signatures, which
suggests that tamoxifen resistant tumors display a highly
proliferative phenotype compared with tamoxifen sensitive
tumors. The examination of genes differentially expressed in
tamoxifen resistant vs. sensitive tumors in breast tumor intrinsic
subtypes revealed that tamoxifen resistance is highly correlated
with the Luminal B and Basal-like subtypes. While Luminal B
tumors have a worse outcome than Luminal A tumors in general
[35], most likely due to enhanced growth factor signaling [36], a
clear association between gene signatures of Luminal subtype and
tamoxifen responsiveness has not been made. Our findings
support this but the similarity between tamoxifen resistant tumors
and both Luminal B and Basal-like subtypes also suggests the
possibility that the increased proliferation signatures in each of
these tumor types could be an underlying factor. In addition, our
analysis also found that the Luminal A tumors can be stratified
into two subgroups using the DE genes and that these two
subgroups have distinctly different outcomes, suggesting that
Figure 5. Prochlorperazine inhibits growth of BT474 cells. Cells were treated 5 mM of prochlorperazine for 5 days and cell proliferation was
measured by methylene blue staining (A) or for 2 days and cyclin E2 mRNA levels were by QPCR (B).
doi:10.1371/journal.pone.0022274.g005
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populations and understanding the relationship between Luminal
subtype and tamoxifen responsiveness requires further study.
Using the Connectivity Map analysis we also linked the gene
expression profiles of several small molecules to those derived from
the three tamoxifen resistant and sensitive tumor datasets.
Although the small molecules utilized in the Connectivity Map
analysis were presumably tested in MCF-7 cells that are sensitive
to tamoxifen, we were able to identify many drugs that induce an
opposite gene expression profile of that seen in tamoxifen resistant
tumors. The top identified compounds belong to different
chemical classes. For example, a HDAC inhibitor (trichostatin
A), a PI3K inhibitor (LY294002), natural compounds, such as
resveretrol and chrysin, and several drugs, including phenothia-
zines (trifluoperazine and thioridazine), monoamine oxidase A
(MAO-A) inhibitor (harmine), and a colchicine analog (trimethyl-
colchicinic acid), were all found to produce an opposite gene
expression profile in MCF-7 or the prostate cancer cell line, PC3.
Validation studies were carried out on three structurally similar
drugs from the phenothiazine family (trifluoperazine, thioridazine,
and prochlorperazine) since they were structurally similar and all
found to down-regulate cyclin E2, a gene differentially expressed
in all three datasets. These drugs were originally designed as anti-
malarial drugs but have been shown to act as anti-histamines, anti-
emetics, suppressants of psychotic symptoms, and anti-choliner-
gics. We confirmed that these drugs reduce cyclin E2 gene
expression and cell proliferation in MCF-7 cells that are resistant
to tamoxifen. The mechanisms by which these drugs act are not
fully clear but they are known to inhibit calmodulin and
prostaglandin synthesis, both of which have the potential to
impact on estrogen receptor (ER) function and alter response to
endocrine therapy [37,38]. In fact, early studies suggested that the
anti-proliferative capacity of trifluoperazine correlated with its
ability to antagonize calmodulin activity and that calmodulin
inhibitors in combination with tamoxifen may have synergistic
activity [39]. Other studies have also suggested an interaction
between phenothiazines and tamoxifen in inducing apoptosis in
cancer cells [40,41]. However, our studies did not show any
interaction between tamoxifen and phenothiazines in any of the
cell types or assays tested. Alternatively, these drugs may act
independently of estrogen receptor and have a general anti-
proliferative effect on breast cancer cells, as suggested by the fact
that they also inhibit proliferation of tamoxifen sensitive MCF-7
cells. Previous studies have suggested that these drugs may
sensitize breast tumors with a multi-drug resistance phenotype
[42], induce apoptosis, potentially in combination with tamoxifen
[40], and/or promote autophagy [43,44].
Exploration of phenothiazines as agents to inhibit growth of
tamoxifen-resistant and sensitive, breast cancer cells requires
further study. Also, since these agents have been used in vivo
testing their ability to reduce tumor burden in preclinical
xenograft models also warrants further investigation.
In conclusion, our findings demonstrate that an integrated
bioinformatics approach to analyze gene expression profiles from
multiple breast tumor datasets can identify important biological
pathways and potential novel therapeutic options for tamoxifen-
resistant breast cancers.
Supporting Information
Figure S1 Growth Response of MCF-7 Cells to Estradiol
and Tamoxifen. MCF-7 cells that spontaneously developed
resistance to tamoxifen were cultured for 5 days in the presence of
10 nM E2, 1 mM 4-hydroxytamoxifen, or both. Cell proliferation
wasmeasured bymethylene blue assayand calculatedaspercentage
of control. Data shown are mean +/2 SE for 3 independent
replicates.
(TIF)
Table S1 Differentially expressed genes between tamoxifen
resistant and sensitive tumors in each data set (adjusted p
value,0.05).
(XLS)
Table S2 GO term functional annotation chart for differentially
expressed genes in each data set using DAVID.
(XLS)
Table S3 List of the canonical pathways and transcription factor
target (TFT) gene sets enriched in tamoxifen resistant tumors in
each data set through GSEA (p,0.05).
(XLS)
Table S4 Transcription factor target (TFT) gene set enrichment
in the Breast Cancer Compendium.
(XLS)
Table S5 List of enriched compounds through the Connectivity
Map analysis.
(XLS)
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